| Code | CSB-RA001950MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to sabirnetug, targeting amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays crucial roles in neuronal development, synaptic plasticity, and cell adhesion. Sequential proteolytic cleavage of APP by β-secretase and γ-secretase generates amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Dysregulation of APP processing and subsequent Aβ accumulation are central to the amyloid cascade hypothesis of neurodegeneration, making APP a critical target for understanding Alzheimer's pathogenesis.
Sabirnetug is an investigational therapeutic antibody designed to bind APP and modulate its processing, potentially reducing pathogenic Aβ production. This biosimilar provides researchers with a valuable tool for studying APP biology, investigating amyloid processing pathways, and exploring therapeutic mechanisms relevant to Alzheimer's disease. It enables examination of APP-related cellular processes and supports the development of amyloid-targeting strategies in neurodegenerative disease research.
There are currently no reviews for this product.